T. Rowe Price Investment Management, Inc. Crispr Therapeutics Ag Transaction History
T. Rowe Price Investment Management, Inc.
- $162 Billion
- Q4 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 3,811,708 shares of CRSP stock, worth $199 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
3,811,708
Previous 2,737,470
39.24%
Holding current value
$199 Million
Previous $129 Million
16.66%
% of portfolio
0.09%
Previous 0.08%
Shares
10 transactions
Others Institutions Holding CRSP
# of Institutions
483Shares Held
64.1MCall Options Held
1.64MPut Options Held
1.93M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.97MShares$469 Million3.09% of portfolio
-
Capital International Investors Los Angeles, CA8.74MShares$457 Million0.07% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$145 Million0.0% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.75MShares$143 Million0.07% of portfolio
-
Nikko Asset Management Americas, Inc.2.75MShares$143 Million1.21% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.07B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....